This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Edgemont Pharmaceuticals, LLC
Drug Names(s): CPI-300, bupropion hydrochloride, Forfivo XL
Description: CPI-300 was formulated using IntelGenx’s proprietary controlled release technology. It contains a new strength of the antidepressant bupropion. CPI-300 was developed to broaden the dosing options for physicians while providing a more convenient dosing option for patients requiring a higher strength of the products currently available.
IntelGenx and Cary
In April 2008, IntelGenx and Cary Pharmaceuticals ratified the Definitive Agreement originally signed on November 5, 2007 to jointly develop and commercialize Carys oral antidepressant, CPI-300, using IntelGenxs proprietary oral delivery technology. Under the terms of the Agreement, IntelGenx secured funding of $2 million for the completion of the product development after closing a private placement worth $2.8 million on March 27, 2008. IntelGenx will be entitled to profit sharing.
In May 2010, IntelGenx executed a Project Transfer Agreement with Cary, whereby Cary assigned its 50% ownership stake in CPI-300 to IntelGenx and agreed that the CPI-300 project will be transferred to IntelGenx. IntelGenx will pay Cary, upon commercialization of CPI-300, 10% of sales royalties received by IntelGenx and 3% of upfront payments received by IntelGenx should a distribution agreement be signed in the future.
IntelGenx and Edgemont
In...See full deal structure in Biomedtracker
Partners: Cary Pharmaceuticals SWK Holdings Corporation IntelGenx Technologies Corp.
Pink Sheet November Full Approvals
Additional information available to subscribers only: